Our results suggest that a wider variety of taste receptor signaling molecules could be applied for development of novel therapeutic agents, as GLP-1 secretagogues and for patients with metabolic diseases, including obesity and T2DM using CuB. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.